H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genenta Science SpA Sponsored ADR (GNTA – Research Report) today and set a price target of $25.00. The company’s shares closed yesterday at $5.72.
Pantginis covers the Healthcare sector, focusing on stocks such as Panbela Therapeutics, Celldex, and Onconova Therapeutics. According to TipRanks, Pantginis has an average return of -2.8% and a 36.27% success rate on recommended stocks.
Genenta Science SpA Sponsored ADR has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $7.08 and a one-year low of $3.90. Currently, Genenta Science SpA Sponsored ADR has an average volume of 2,651.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genenta Science SPA is a clinical-stage biotechnology company pioneering the development of lentivirus-based first-in-class gene and cell therapies in cancer.
Read More on GNTA:
- Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
- Genenta Science SpA(ADR) trading resumes
- Genenta Science SpA(ADR) trading halted, volatility trading pause
- Genenta Science assumed with a Buy at Roth MKM
- Genenta Science receives Orphan Drug Designation from EC for Temferon
